beta-alanine has been researched along with Bacterial Pneumonia in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " All the adverse events were recorded." | 1.38 | [The clinical efficacy and safety of panipenem-betamipron in treatment of moderate to severe pulmonary infection]. ( , 2012) |
| " All patients were 65 years of age or older, and were given PAPM/BP at a total daily dosage range of 0." | 1.31 | Evaluation of panipenem/betamipron (PAPM/BP) in pneumonia in elderly patients. ( Fukushima, Y; Kitamura, S; Motojima, S; Nakamoto, T; Shibuya, Y; Tani, G; Yatagai, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mendez, MP | 1 |
| Monroy, YK | 1 |
| Du, M | 1 |
| Preston, AM | 1 |
| Tolle, L | 1 |
| Lin, Y | 1 |
| VanDussen, KL | 1 |
| Samuelson, LC | 1 |
| Standiford, TJ | 1 |
| Curtis, JL | 1 |
| Beck, JM | 1 |
| Christensen, PJ | 1 |
| Paine, R | 1 |
| Shibuya, Y | 1 |
| Kitamura, S | 1 |
| Tani, G | 1 |
| Fukushima, Y | 1 |
| Yatagai, S | 1 |
| Nakamoto, T | 1 |
| Motojima, S | 1 |
3 other studies available for beta-alanine and Bacterial Pneumonia
| Article | Year |
|---|---|
Overexpression of sICAM-1 in the alveolar epithelial space results in an exaggerated inflammatory response and early death in Gram negative pneumonia.
Topics: Acrylamides; Animals; beta-Alanine; Cells, Cultured; Chemokine CXCL2; Chemotaxis; Disease Models, An | 2011 |
[The clinical efficacy and safety of panipenem-betamipron in treatment of moderate to severe pulmonary infection].
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Alanine; Community-Acquired Infections; Cross Infection; Dr | 2012 |
Evaluation of panipenem/betamipron (PAPM/BP) in pneumonia in elderly patients.
Topics: Aged; Aged, 80 and over; Bacteria; beta-Alanine; Drug Therapy, Combination; Female; Humans; Male; Pn | 2002 |